Published in Women's Health Weekly, January 5th, 2012
"The median survival of patients with metastatic breast cancer is two to three years and for patients with "triple-negative" disease, the prognosis is even more grim," said Thomas Davis, MD, Chief Medical Officer of Celldex Therapeutics. "A previous Phase 1/2 single arm study of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.